DAPT: Who, when and for how long? [Podcast]

24 Aug 2022

In this podcast, Prof. David Brieger and A/Prof. Nicholas Cox discuss the value of dual antiplatelet therapy (DAPT) in reducing the risk of recurrent events post-acute coronary syndrome or percutaneous coronary intervention, how to personalise therapy in patients at high bleeding risk, and what the data tells us about the optimal duration of DAPT.


Prof. David Brieger is Head of Cardiology, Concord Hospital and Professor of Cardiology, Concord Clinical School, the University of Sydney.





A/Prof. Nicholas Cox is a Consultant and Interventional Cardiologist. He is the director of Cardiology for Western Health and on the Epworth Hospital Cardiac Sciences Clinical Institute Committee.





This podcast was sponsored by Astra Zeneca. Any views expressed are those of the experts alone and do not necessarily reflect the views of the sponsor. Before prescribing, please review the Brilinta product information via the TGA website. Treatment decisions based on information in this podcast are the responsibility of the prescribing physician.

Already a member?

Login to keep reading.

Email me a login link